Developing a multiplex gene editing approach targeting viral infection

Cell & Gene Therapy Insights 2023; 9(9), 1287–1292

DOI: 10.18609/cgti.2023.165

Published: 8 November 2023
TJ Cradick

David McCall, Senior Editor, Cell & Gene Therapy Insights, speaks to TJ Cradick, Chief Scientific Officer, Excision BioTherapeutics, reflecting on his 20-year career in gene editing and discussing the cutting edge in multiplexing with CRISPR